WB-DW-MRI at 3T in relapsed multiple myeloma:early response assessment
Research type
Research Study
Full title
Pilot study to evaluate diffusion-weighted MRI (DW-MRI) Whole Body MRI in relapsed Multiple Myeloma at 3T: test-retest, early response assessment and exploratory imaging of renal function.
IRAS ID
150729
Contact name
Andrea Rockall
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
In those patients who have been treated for multiple myeloma (MM), a return of the disease (recurrence or relapse) is a relatively common occurence. In those cases a different treatment can then be attempted to control the disease. Some patients will respond to this treatment and some will not. Some patients will respond more quickly and better to this treatment than others. Currently assessment for response to treatment includes clinical assessment, blood tests, bone marrow aspirate and/or with conventional (currently used) MRI scans. The aim of our study is to assess whether new MRI techniques (DW-MRI) are able to improve early assessment of these new treatments.
In addition, we know that multiple myeloma commonly affects the kidneys and causes them to lose function. This is usually assessed with blood tests. We also aim to investigate whether these new MRI techniques can also be used to investigate how the kidneys are functioning to see if kidney damage can be detected earlier.
REC name
London - Queen Square Research Ethics Committee
REC reference
14/LO/1833
Date of REC Opinion
24 Oct 2014
REC opinion
Favourable Opinion